Head to Head Review: MediPharm Labs (OTCMKTS:MEDIF) vs. Phathom Pharmaceuticals (NASDAQ:PHAT)

MediPharm Labs (OTCMKTS:MEDIF) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends and institutional ownership.

Earnings & Valuation

This table compares MediPharm Labs and Phathom Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediPharm Labs	N/A	N/A	N/A	N/A	N/A
Phathom Pharmaceuticals	$175.11 million	4.24	-$221.25 million	($1.28)	-7.17

MediPharm Labs has higher earnings, but lower revenue than Phathom Pharmaceuticals.

Insider & Institutional Ownership

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares MediPharm Labs and Phathom Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MediPharm Labs	N/A	N/A	N/A
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%

Analyst Recommendations

This is a breakdown of recent recommendations for MediPharm Labs and Phathom Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediPharm Labs	0	0	0	0	0.00
Phathom Pharmaceuticals	1	0	6	1	2.88

Phathom Pharmaceuticals has a consensus target price of $22.86, indicating a potential upside of 148.99%. Given Phathom Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than MediPharm Labs.

Summary

Phathom Pharmaceuticals beats MediPharm Labs on 7 of the 9 factors compared between the two stocks.

About MediPharm Labs

MediPharm Labs Corp., a pharmaceutical company, engages in the production and sale of purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower and pre-roll cannabis products. In addition, the company offers cannabis related medical information and services; and medical cannabis clinic services. MediPharm Labs Corp. was founded in 2015 and is headquartered in Barrie, Canada.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.